A clinical efficacy analysis of single-port thoracoscopic lung resection in the treatment of male patients with non-small cell lung cancer using surface localization and CT-guided sclerosant

Background: This study was done to explore the effectiveness of single-port thora-coscopic anatomical lung wedge resection in conjunction with Computed Tomography (CT)-guided sclerosants and surface localization for treating male patients diagnosed with non-small cell lung cancer (NSCLC). Methods: A retrospective analysis was conducted on the clinical data of 122 male NSCLC patients treated at our hospital from January 2020 to January 2022. Patients were divided into a study group (61 cases receiving single-port thoracoscopic anatomical wedge resection + CT-guided sclerosant and surface localization) and a control group (61 cases receiving single-port thoracoscopic anatomical wedge resection). The perioperative indicators, serum tumor markers, pulmonary function indicators and stress response indicators were compared between the two groups. Results: Postoperatively, the study group had shorter operation time (124.15 ± 12.52 minutes), hospital stay (7.38 ± 0.73 days), drainage tube removal time (5.75 ± 0.57 days), and lower levels of Cytokeratin 19 fragment (CYFRA21-1)(3.03 ± 0.51 ng/mL), Carcino-Embryonic Antigen (CEA) (9.77 ± 0.96 ng/mL), Cancer Antigen 19-9 (CA199) (45.57 ± 4.86 U/mL), Squamous Cell Carcinoma Antigen (SCC)(21.29 ± 2.38 g/L), Epinephrine (E) (60.87 ± 6.41 pg/mL), Norepinephrine (NE) (185.32± 18.53 pg/mL), and Cortisol (Cor) (97.63 ± 9.76 ng/mL) compared to the control group (operation time: 136.85 ± 13.77 minutes; hospital stay: 9.67 ± 0.91 days; drainage tube removal time: 7.23 ± 0.69 days; CYFRA21-1: 4.87 ± 0.55 ng/mL; CEA: 12.68 ± 1.32 ng/mL; CA199: 16.38 ± 1.59 U/mL; SCC: 10.58 ± 1.12 g/L; E: 77.86 ± 7.86 pg/mL; NE: 226.76 ± 22.66 pg/mL; Cor: 119.87 ± 11.89 ng/mL). Conclusions: In summary, the integration of thoracoscopic anatomical lung wedge resection through a single port with CT-guided sclerosant and surface localization has been shown to bring about notable improvements in perioperative parameters, preserve lung function and alleviate stress reactions in male patients diagnosed with NSCLC.

Single-port thoracoscopic lung resection; CT-guided sclerosant; Surface localization; Non-small cell lung cancer; Clinical efficacy

[1] Chen P, Liu Y, Wen Y, Zhou C. Non‐small cell lung cancer in China. Cancer Communications. 2022; 42: 937–970.

[2] Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020; 198: 897–907.

[3] Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Critical Reviews in Oncology/Hematology. 2021; 157: 103194.

[4] Li Y, Zhang M, Shi A, Liu P, Zhang H, Zhang Y, et al. Magnetic anchor technique-assisted thoracoscopic lobectomy in beagles. Scientific Reports. 2022; 12: 11916.

[5] Wang X, Qiao Z, Aramini B, Lin D, Li X, Fan J. Potential biomarkers for immunotherapy in non-small-cell lung cancer. Cancer Metastasis Reviews. 2023; 42: 661–675.

[6] Wang LM, Yadav R, Serban M, Arias O, Seuntjens J, Ybarra N. Validation of an orthotopic non-small cell lung cancer mouse model, with left or right tumor growths, to use in conformal radiotherapy studies. PLOS ONE. 2023; 18: e0284282.

[7] Liu J, Pandya P, Afshar S. Therapeutic advances in oncology. International Journal of Molecular Sciences. 2021; 22: 2008.

[8] Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Current surgical indications for non-small-cell lung cancer. Cancers. 2022; 14: 1263.

[9] Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z, et al. Current treatments for non-small cell lung cancer. Frontiers in Oncology. 2022; 12: 945102.

[10] Steinfort DP, Antippa P, Rangamuwa K, Irving LB, Christie M, Chan E, et al. Safety and feasibility of a novel externally cooled bronchoscopic radiofrequency ablation catheter for ablation of peripheral lung tumours: a first-in-human dose escalation study. Respiration. 2023; 102: 211–219.

[11] Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, et al. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Frontiers in Oncology. 2023; 13: 1011810.

[12] Mizuno T, Konno H, Nagata T, Isaka M, Ohde Y. Osteogenic and brain metastases after non-small cell lung cancer resection. International Journal of Clinical Oncology. 2021; 26: 1840–1846.

[13] Cooper A, Chaft JE, Bott MJ. Induction therapy for non-small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. 2024; 168: 411–416.

[14] O’Brien J, Bodor JN. Perioperative immunotherapy in non-small cell lung cancer. Current Treatment Options in Oncology. 2023; 24: 1790–1801.

[15] Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor immunology and immunotherapy of non-small-cell lung cancer. Cold Spring Harbor Perspectives in Medicine. 2022; 12: a037895.

[16] Saw SPL, Ong B, Chua KLM, Takano A, Tan DSW. Revisiting neoadjuvant therapy in non-small-cell lung cancer. The Lancet Oncology. 2021; 22: e501–e516.

[17] Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology. Current Oncology. 2022; 29: 1828–1839.

[18] Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. Journal of the National Comprehensive Cancer Network. 2021; 19: 254–266.

[19] Gravier FE, Smondack P, Prieur G, Medrinal C, Combret Y, Muir JF, et al. Effects of exercise training in people with non-small cell lung cancer before lung resection: a systematic review and meta-analysis. Thorax. 2022; 77: 486–496.

[20] Rosell R, Jain A, Codony-Servat J, Jantus-Lewintre E, Morrison B, Ginesta JB, et al. Biological insights in non-small cell lung cancer. Cancer Biology & Medicine. 2023; 20: 500–518.

[21] Namkaew J, Zhang J, Yamakawa N, Hamada Y, Tsugawa K, Oyadomari M, et al. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Letters. 2024; 582: 216509.

[22] Jiang Z, Xu C, Wang W, Zhang Y, Huang J, Xie Y, et al. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells. Pharmacological Research. 2021; 169: 105656.